

PATIENT INFORMATION:

Fax completed form, insurance information, and clinical documentation to 470.922.3656

Patient Name: _____ DOB: _____ Phone: _____
Patient Status: New to Therapy Continuing Therapy **Next Treatment Date:** _____

MEDICAL INFORMATION

Diagnosis: Chronic Gouty Arthropathy w/tophus (tophi)
 Chronic Arthropathy w/o mention of tophus (tophi)
 Other: _____

ICD-10 Code: _____

Weight: _____ lbs Allergies: _____

THERAPY ORDER

Krystexxa Dose: 8mg IV in 250mL of NS IV over 120 minutes
*Patient will be observed 1 hour post infusion

Frequency: Every 2 weeks

Refills: 1 year Other: _____

If you would like Biocare Infusion to dispense the methotrexate, please check appropriate box:
 Methotrexate 15mg PO weekly x1 year (to begin 4 weeks prior to Krystexxa)

Protocol Pre-Medication Orders: Solu-Medrol 125mg IV, Benadryl 25mg PO/IV
**Patient advised to take antihistamine day before infusion*

Lab Orders: Serum uric acid 24-72 hours prior to infusion
 G6PD serum level (required prior to first dose)
 Other lab orders: _____

Labs: Required labs to be drawn by Infusion Center Referring Provider

Other orders: _____

PROVIDER INFORMATION

By signing this form and utilizing our services, you are authorizing *Biocare Infusion*, and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient

Provider Name: _____ Signature: _____ Date: _____

Provider NPI: _____ Phone: _____ Fax: _____ Contact Person: _____

Opt out of Biocare Infusion selecting site of care (if checked, please list site of care):

PREFERRED LOCATION

City: _____ State: _____

View our locations here:



PATIENT INFORMATION:

Patient Name: _____ DOB: _____

REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

- Include signed and completed order (MD/prescriber to complete page 1)
- Include patient demographic information and insurance information
- Include patient's medication list
- Krystexxa Service Request form
- Supporting clinical notes (H&P) to support primary diagnosis

*Product information suggests the co-administration of weekly oral methotrexate 15mg and folic acid or folinic acid

supplementation. Krystexxa alone may be used in patients where methotrexate is contraindicated or not clinically appropriate.

If co-administering with methotrexate, start weekly methotrexate and folic or folinic acid supplementation at least 4 weeks prior to initiating, and throughout treatment with Krystexxa*

Will the patient co-administer methotrexate or other immunomodulation therapy?

Yes No If yes, which drug? _____

Documentation of frequency and date of flares in the last 18 months (either attach or document here): _____

Has the patient tried and failed Allopurinol/Uloric, Colchicine, or Probenecid?

Yes No If yes, which drug(s)? _____

Labs attached, including

Baseline serum uric acid (**required**)

G6PD serum level (**required**)

It is recommended that patients discontinue oral urate-lowering medications before starting Krystexxa

Other medical necessity: _____

Biocare Infusion will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance